This Analyst Predicts $396 For Eli Lilly, Plus Raymond James Slashes PT On This Stock By Over 73%
Raymond James cut the price target for PolyPid Ltd. (NASDAQ: PYPD) from $15 to $4. PolyPid shares fell 7.7% to $1.32 in pre-market trading.
Piper Sandler Upgrades Organon to Overweight, Lowers Price Target to $34
Piper Sandler analyst David Amsellem upgrades Organon (NYSE:OGN) from Neutral to Overweight and lowers the price target from $37 to $34.
This Women Health Stock Gets Analyst Downgrade On ‘Approvability Issues, Restructuring’
HC Wainwright has downgraded ObsEva SA (NASDAQ:OBSV) from a Buy to Neutral without a price target. Late last month, the FDA notified…
Recap Of Wednesday’s Biotech Catalysts – End Of the Day Summary
The U.S. Food and Drug Administration (FDA) has approved Bluebird bio’s (NASDAQ:BLUE) lead asset ZYNTEGLO (betibeglogene autotemcel) to treat…
Organon Expects Lower EBITDA Margin For FY22, Clocks Mixed Q2 Earnings
Organon & Co’s (NYSE:OGN) Q2 sales decreased 1% Y/Y to $1.59 billion, beating the consensus of $1.54 billion. The sales…
Earnings Scheduled For August 4, 2022
Companies Reporting Before The Bell
• Toyota Motor (NYSE:TM) is projected to report earnings for its first quarter.
Origin Protocol’s OGV Airdrop Launches Today: Ethereum Protocol To Scale NFTs And Stablecoin Yields
Origin Protocol will be undertaking its Origin Dollar Governance (CRYPTO: OGV) airdrop on Tuesday.
Organon Enters Into Global License Agreement To Commercialize Henlius’ Investigational Perjeta And Prolia/Xgeva Biosimilar Candidates
Organon (NYSE:OGN), a global women’s health company with deep expertise in biosimilar commercialization, today announced that it has entered into an agreement with Shanghai Henlius Biotech, Inc. (2696.HK), whereby
Earnings Scheduled For May 5, 2022
Companies Reporting Before The Bell
• Mirum Pharmaceuticals (NASDAQ:MIRM) is expected to report quarterly loss at $1.34 per share on revenue of $8.46 million.